• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pirfenidone.

作者信息

Richeldi Luca, Yasothan Uma, Kirkpatrick Peter

出版信息

Nat Rev Drug Discov. 2011 Jul;10(7):489-90. doi: 10.1038/nrd3495.

DOI:10.1038/nrd3495
PMID:21837822
Abstract
摘要

相似文献

1
Pirfenidone.吡非尼酮
Nat Rev Drug Discov. 2011 Jul;10(7):489-90. doi: 10.1038/nrd3495.
2
Pirfenidone for idiopathic pulmonary fibrosis.吡非尼酮用于特发性肺纤维化
Lancet. 2011 May 21;377(9779):1727-9. doi: 10.1016/S0140-6736(11)60546-1. Epub 2011 May 13.
3
Is pirfenidone effective for idiopathic pulmonary fibrosis?吡非尼酮对特发性肺纤维化有效吗？
Medwave. 2017 Jan 17;17(Suppl1):e6843. doi: 10.5867/medwave.2017.6844.
4
Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.与吡非尼酮用于特发性肺纤维化相关的严重结肠炎。
Ann Am Thorac Soc. 2016 Aug;13(8):1430-2. doi: 10.1513/AnnalsATS.201602-118LE.
5
[Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].抗纤维化药物吡非尼酮（艾思瑞）治疗特发性肺纤维化的药理特性及临床疗效
Nihon Yakurigaku Zasshi. 2009 Aug;134(2):97-104. doi: 10.1254/fpj.134.97.
6
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.特发性肺纤维化的用力肺活量——美国食品药品监督管理局对吡非尼酮和尼达尼布的审评
N Engl J Med. 2015 Mar 26;372(13):1189-91. doi: 10.1056/NEJMp1500526.
7
Pirfenidone treatment of idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14.
8
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化的安全性和不良反应事件管理。
Eur Respir Rev. 2017 Dec 6;26(146). doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31.
9
Pirfenidone: in idiopathic pulmonary fibrosis.吡非尼酮：在特发性肺纤维化中的应用。
Drugs. 2011 Sep 10;71(13):1721-32. doi: 10.2165/11207710-000000000-00000.
10
[Antifibrotic treatment].[抗纤维化治疗]
Dtsch Med Wochenschr. 2014 Dec;139(49):2523-5. doi: 10.1055/s-0034-1387450. Epub 2014 Nov 25.

引用本文的文献

1
Precise control of selective nitrogen atom insertion into five-membered cyclic β-ketoesters.将选择性氮原子插入五元环状β-酮酯的精确控制。
Nat Commun. 2025 Jul 19;16(1):6660. doi: 10.1038/s41467-025-62034-z.
2
Biodegradable Double-Layer Hydrogels with Sequential Drug Release for Multi-Phase Collaborative Regulation in Scar-Free Wound Healing.用于无瘢痕伤口愈合中多阶段协同调控的具有顺序药物释放功能的可生物降解双层水凝胶
J Funct Biomater. 2025 May 7;16(5):164. doi: 10.3390/jfb16050164.
3
Design, development, and preclinical evaluation of pirfenidone-loaded nanostructured lipid carriers for pulmonary delivery.

本文引用的文献

1
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
2
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.特发性肺纤维化：诊断和管理的循证指南（美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布）
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
3
Strategies for treating idiopathic pulmonary fibrosis.
用于肺部给药的吡非尼酮纳米结构脂质载体的设计、开发及临床前评价
Sci Rep. 2025 Apr 3;15(1):11390. doi: 10.1038/s41598-025-90910-7.
4
Intra-articular sustained-release of pirfenidone as a disease-modifying treatment for early osteoarthritis.吡非尼酮关节腔内缓释作为早期骨关节炎的疾病修饰治疗方法
Bioact Mater. 2024 May 23;39:255-272. doi: 10.1016/j.bioactmat.2024.05.028. eCollection 2024 Sep.
5
Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.吡非尼酮和尼达尼布治疗间质性肺疾病的文献计量分析
Heliyon. 2024 Apr 15;10(8):e29266. doi: 10.1016/j.heliyon.2024.e29266. eCollection 2024 Apr 30.
6
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.研究吡非尼酮作为一种有前途的抗炎、抗纤维化、抗氧化、抗凋亡、抗肿瘤和/或抗 SARS-CoV-2 的可能机制。
Life Sci. 2022 Nov 15;309:121048. doi: 10.1016/j.lfs.2022.121048. Epub 2022 Oct 7.
7
Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation.吡非尼酮通过抑制NLRP3炎性小体激活改善实验性肺动脉高压中的肺动脉压力和内膜增生重塑。
Pulm Circ. 2022 Jul 1;12(3):e12101. doi: 10.1002/pul2.12101. eCollection 2022 Jul.
8
Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.吡非尼酮对甲状腺相关眼病患者眼眶成纤维细胞转化生长因子-β1诱导的肌成纤维细胞分化及细胞外基质稳态失衡的影响
Biomolecules. 2021 Sep 29;11(10):1424. doi: 10.3390/biom11101424.
9
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction.吡非尼酮在射血分数保留的心力衰竭中应用的理论依据。
Front Cardiovasc Med. 2021 Apr 22;8:678530. doi: 10.3389/fcvm.2021.678530. eCollection 2021.
10
Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.用于胰腺导管腺癌诊断和治疗的定制纳米材料。
Adv Sci (Weinh). 2021 Feb 12;8(7):2002545. doi: 10.1002/advs.202002545. eCollection 2021 Apr.
特发性肺纤维化的治疗策略。
Nat Rev Drug Discov. 2010 Feb;9(2):129-40. doi: 10.1038/nrd2958. Epub 2010 Jan 22.
4
Pirfenidone in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
5
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.吡非尼酮对博莱霉素诱导的肺纤维化仓鼠模型转录水平转化生长因子-β基因表达的影响。
J Pharmacol Exp Ther. 1999 Oct;291(1):367-73.
6
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.吡非尼酮的饮食摄入可改善博来霉素诱导的仓鼠肺纤维化。
J Lab Clin Med. 1995 Jun;125(6):779-85.